a Oficina de Comercialización de Tecnología, Centro Universitario de Vinculación y Transferencia de Tecnología , Benemérita Universidad Autónoma de Puebla , Puebla , México.
b Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente , Instituto Mexicano del Seguro Social , Metepec, Puebla , Mexico.
Expert Opin Ther Pat. 2019 May;29(5):311-314. doi: 10.1080/13543776.2019.1608947. Epub 2019 Apr 24.
LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer. Authors of patent US2018271940 propose a method to eradicate cancer that utilizes the combination of LAG-3Ig and anti-PD-1 or anti-PD-L1 antibodies. Areas covered: Patent US2018271940 describes a method consisting of the utilization of either a pharmaceutical cocktail containing LAG-3Ig and an anti-PD-1 or anti-PD-L1 antibody for activation of T cells as a potential for the treatment of cancer. Expert opinion: Data supporting the patent demonstrate the ability of LAG-3Ig and PD-1/PD-L1 to be useful in T cells activation, in addition to the reports showing that LAG-3 and anti-PD-1 and PD-L1 antibodies are therapeutic agents against cancer. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.
LAG-3 是癌症中的检查点抑制剂，它协调抗原特异性淋巴细胞增殖的下调。非常需要发现和开发新的治疗方法，专注于抑制 LAG-3 的作用，从而改善各种癌症中的免疫反应。美国专利 US2018271940 的作者提出了一种利用 LAG-3Ig 和抗 PD-1 或抗 PD-L1 抗体联合来消灭癌症的方法。
美国专利 US2018271940 描述了一种利用包含 LAG-3Ig 和抗 PD-1 或抗 PD-L1 抗体的药物鸡尾酒来激活 T 细胞的方法，作为治疗癌症的一种潜力。
支持该专利的数据表明，LAG-3Ig 和 PD-1/PD-L1 能够在 T 细胞激活中发挥作用，此外还有报告表明 LAG-3 与抗 PD-1 和 PD-L1 抗体是癌症的治疗药物。尽管所提出的方法学非常有趣且有前途，但仍需要进一步研究来评估这些发明在癌症中的临床适用性。
